We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Proteros Appoints Dr Klaus Hinterding
News

Proteros Appoints Dr Klaus Hinterding

Proteros Appoints Dr Klaus Hinterding
News

Proteros Appoints Dr Klaus Hinterding

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Proteros Appoints Dr Klaus Hinterding"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Dr Hinterding brings to Proteros considerable pharmaceutical industry experience that spans early research through to clinical development in various therapeutic areas.

At Novartis, his research contributed to the understanding of the mode-of-action of GilenyaTM, licensed for the treatment of multiple sclerosis, and he led the team that discovered a selective S1P-receptor agonist, currently in Phase II for the same indication. As Life Cycle Leader at Roche he implemented an innovative development and commercial strategy for one of Roche´s leading late-stage development candidates that culminated in a multi-thousand patient clinical program in cardiovascular disease. Dr. Hinterding has led various international research & development collaborations and is an author and inventor of more than 20 patents and publications. He was a post-doctoral fellow at Harvard University and received his PhD in organic Chemistry from the University of Karlsruhe.

Torsten Neuefeind, founder and CEO of Proteros, said: “Klaus’ significant background in medicinal chemistry, drug discovery and clinical development will have an immediate impact on Proteros’ growing integrated lead discovery business. Klaus will be responsible for growing the organization that supports our clients as they rely on Proteros to deliver analytical services of crystallography, compound profiling, proteins and increasingly lead compounds, through innovative, integrated structure guided drug discovery collaborations. We welcome Klaus to Proteros.”

Advertisement